Sign inJoin waitlistJoin the waitlist

YV

Yazhini Vallatharasu

Physician · ThedaCare Regional Medical Center-Appleton

Credentials: · · · · ·

History

ThedaCare Regional Medical Center-Appleton
2020–Present

Hematology and Medical Oncology
Gundersen Lutheran Medical Foundation
2016–2019
Internal Medicine
Gundersen Lutheran Medical Foundation
2013–2016
Doctor of Medicine
2008–2012
Stanley Medical College SMCClass of
2008–2011

Research

Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody-Drug Conjugate
Review · Drugs in R&D · 2018 · 29 citations
Utilization of Surgery and Its Impact on Survival in Patients With Early Stage Small-cell Lung Cancer in the United States
Clinical Lung Cancer · 2020 · 24 citations
Twenty-year Experience with Genitourinary Lymphoma at a Community Hospital
Clinical Medicine & Research · 2021 · First of 3 authors · 10 citations

Dipesh Uprety
6 papers · 6 as a fellow
AB
Amir Bista
5 papers · 5 as a fellow
LA
Lubina Arjyal
3 papers · 3 as a resident
BP
Benjamin Parsons
2 papers
DM
David Marinier
2 papers
KZ
Kehua Zhou
2 papers
AC
Adithya Chennamadhavuni
1 paper · 1 as a fellow
Aniqa Faraz
1 paper · 1 as a fellow
Bilal Lashari
1 paper · 1 as a resident
Binod Dhakal
1 paper
JD
Jake Deviley
1 paper
JF
John Farnen
1 paper

Clinical trials

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2032
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027